Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and raises the price target from $35 to $36.
Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and raises the price target from $35 to $36.